Skip to main content
. 2014 Jul 8;25(8):730–739. doi: 10.1089/hum.2014.006

FIG. 4.

FIG. 4.

ErbB2369–377-specific T cells show potent IFN-γ production in response to ErbB2-peptide-loaded targets and ErbB2-expressing cancer cell lines in vitro. (A) ErbB2 or MART1 TCR-transduced T cells were cocultured with T2 cells loaded with HLA-A2-restricted ErbB2369–377 or with MART126–35 for 18 hr. (B) ErbB2 or MART1 TCR-transduced T cells were cultured alone (none) or stimulated overnight with human HLA-A2-restricted ErbB2+-established cancer cell lines. SKOV-3 (HLA-A2− ErbB2+) and CEM (HLA-A2− ErbB2−) served as negative control tumor targets. (C) CD8+ T cells transduced with the ErbB2369–377-specific TCR as well as the control MART1 TCR were incubated 11 days after transduction for 18 hr with T2 cells pulsed with a range of titrated concentrations of ErbB2369–377 peptide. T2 pulsed with MART126–35 peptide served as negative control target T cells. For all assays, IFN-γ was quantified from cell-free supernatants by ELISA and is reported as the mean concentration (pg/ml)±SEM of duplicate wells.